

# Highly Enantioselective [3 + 2]-Annulation of Isatin-Derived Morita– Baylis–Hillman Adducts with Cyclic Sulfonimines

Feng Wei, Hong-Yan Huang, Neng-Jun Zhong, Chun-Ling Gu, Dong Wang, and Li Liu\*

Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

University of Chinese Academy of Sciences, Beijing 100049, China

**Supporting Information** 



**ABSTRACT:** An organocatalytic [3 + 2]-annulation between isatin-derived Morita–Baylis–Hillman adducts and cyclic sulfonimines has been developed in high yields with excellent enantio- and diastereoselectivities via an allylic nitrogen-ylide intermediate. The reaction provides access to heavily substituted aza-spirooxindole derivatives, which also contain ring fused cyclic sultams.

D ue to the important structural motif and biological activities of aza-spirooxindoles A, many literature reports have focused on the asymmetric synthesis of these compounds.<sup>1</sup>On the other hand, the chiral cyclic sultams B and sulfamidates exhibit a broad spectrum of biological activities<sup>2</sup> and serve as chiral auxiliaries.<sup>3</sup> The construction of the molecule C bearing both structural units is very attractive and interesting (Figure 1). It has been suggested that the



Figure 1. Biological structures containing aza-spirooxindoles and cyclic sultams.

construction of an aza-five-membered ring would be realized through [3 + 2]-cycloaddition of a 1,3-dipole with imine compounds, which was considered a powerful and efficient approach to access azacyclopentanes.

As is known, the cinchona alkaloids and their derivatives have been widely used as efficient tertiary-amine catalysts in many enantioselective reactions.<sup>4</sup> Meanwhile, Morita–Baylis–Hillman (MBH) adducts, owing to their dense functionalities, have been illustrated as valuable synthons and starting materials in the synthesis of many biologically active molecules and natural products.<sup>5</sup> As powerful precursors of 1,3-dipoles, MBH adducts have been extensively utilized in the construction of multifunctional cyclic compounds under nucleophilic tertiaryphosphine or tertiary-amine organocatalysis via allylic phosphorus and nitrogen ylide intermediates.<sup>6</sup> Since Lu and coworkers<sup>7</sup> reported the seminal phosphine-catalyzed [3 + 2]annulation of MBH carbonates with maleimides, the annulations of MBH adducts with various dipolarophiles through allylic phosphorus ylide have achieved great progress in the past decades.<sup>8</sup> However, up to now, there have been limited reports on the use of cinchona alkaloids as chiral tertiary-amine catalysts to perform annulations through an allylic nitrogen ylide intermediate.<sup>9</sup> Recently, our group<sup>9a</sup> and Zhou's group, <sup>9b</sup> respectively, reported a [3 + 2]-annulation of MBH adducts with carbonyl compounds via an allylic nitrogen ylide intermediate in which cinchona alkaloids as a chiral tertiary-amine catalyst efficiently effected stereocontrol and avoided generation of the olefination products.<sup>10</sup> Due to the stability and easily modified property of chiral tertiary-amine catalyst, we wondered whether the strategy could be employed in asymmetric [3 + 2]-annulations of MBH adducts with imines. Although achiral tertiary-phosphine catalyzed [3 + 2]annulation of MBH adducts with imines could proceed smoothly, all the products were racemic mixtures.<sup>11</sup> Ma and co-workers<sup>11b</sup> attempted to extend this annulation to being enantioselective by using chiral bisphosphine catalysts, but the results were not significant (up to 54% ee). Herein, we would like to report an asymmetric [3 + 2]-annulation of isatinderived MBH carbonates with cyclic sulfonimine under cyclic cinchona alkaloid catalysis to afford chiral aza-spirooxindoles

Received:February 12, 2015Published:March 17, 2015

containing two newly created adjacent quaternary centers with high enantioselectivities.

In initial attempts, the [3 + 2]-annulation of MBH carbonate 1a with cyclic sulfonimine 2a in the presence of 10 mol %  $\beta$ isocupreidine ( $\beta$ -ICD, catalyst C1) was carried out in chloroform at -40 °C for 2 h (Figure 2) (Table 1, entry 1).



Figure 2. Chiral tertiary-amine catalysts.



NC BocO N Bn +		CO2Et Co2Et		EtO <sub>2</sub> CN Bn 3aa		
entry	catalyst (mol %)	solvent	time (h)	yield (%) <sup>b</sup>	dr <sup>c</sup>	ee (%) <sup>d</sup>
1	C1 (10)	CHCl <sub>3</sub>	2	trace	—	_
2	C2 (10)	CHCl <sub>3</sub>	2	91	>20:1	93
3	C3 (10)	CHCl <sub>3</sub>	2	92	>20:1	92
4	C4 (10)	CHCl <sub>3</sub>	2	90	>20:1	93
5	C5 (10)	CHCl <sub>3</sub>	2	95	>20:1	98
6	C5 (10)	$CH_2Cl_2$	2	94	>20:1	97
7	C5 (10)	toluene	2	95	>20:1	94
8	C5 (10)	THF	4	85	>20:1	90
9	C5 (10)	CH <sub>3</sub> CO <sub>2</sub> Et	1	95	>20:1	91
10	C5 (5)	CHCl <sub>3</sub>	5	92	>20:1	98
11	C5 (1)	CHCl <sub>3</sub>	20	91	>20:1	97

<sup>*a*</sup>The reaction was conducted with **1a** (0.11 mmol) and **2a** (0.1 mmol) in solvent (1.0 mL) at -40 °C in the presence of catalyst. <sup>*b*</sup>Isolated yields of diastereoisomer mixture. <sup>*c*</sup>The dr was determined by <sup>1</sup>H NMR spectroscopy. <sup>*d*</sup>The ee value was determined by chiral HPLC.

Unfortunately, only a trace amount of the [3 + 2]-annulation product was detected. To our delight, when OH of C1 was changed to OMe and catalyst C2 was employed in the reaction of 1a with 2a under the same conditions, the annulation product 3aa was obtained in 91% yield with >20:1 dr and 93% ee (Table 1, entry 2). For catalyst C3 with a phenyl group at the C-6' position, an increase of the ee value of 3aa was not observed (Table 1, entry 3). Moreover, if the phenyl group at C-6' was replaced by a bulkier naphthyl group, in the case of catalyst C4, the yield and enantioselectivity of the reaction of 1a with 2a remained identical (Table 1, entry 4). However, by using the easily available catalyst C5 without any substituent at the C-6' position, it was found that the yield of corresponding product 3aa was increased to 95% with >20:1 dr and 98% ee (Table 1, entry 5). If the catalyst loading was decreased to 5 or even 1 mol %, the yields of **3aa** could still remain >90% but the reaction time was prolonged to 5 or 20 h (Table 1, entries 10–11). Then the solvent effect was also examined. When the solvent was changed to dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), toluene, tetrahydrofuran (THF), and ethyl acetate, no better results were achieved (Table 1, entries 6–9). Therefore, the best results were obtained in CHCl<sub>3</sub> at -40 °C in the presence of catalyst C5.

Under the optimized reaction conditions, the scope of MBH carbonates 1 derived from isatin in the reaction with cyclic sulfonimine 2a was investigated. The results are summarized in Scheme 1. In general, the MBH adducts bearing both electron-





<sup>*a*</sup>The reaction was conducted with **1a** (0.11 mmol) and **2a** (0.1 mmol) in solvent (1.0 mL) at -40 °C in the presence of 10 mol % catalyst for 2 h. <sup>*b*</sup>Isolated yields of diastereoisomer mixture. <sup>*c*</sup>The dr was determined by <sup>1</sup>H NMR spectroscopy. <sup>*d*</sup>The ee value was determined by chiral HPLC. <sup>*e*</sup>In parentheses, 5 mol % catalyst, 5 h. <sup>*f*</sup>The reaction was performed at room temperature for 20 h.

withdrawing and -donating substituents on the C5 and/or C7 positions afforded the corresponding [3 + 2]-annulation products **3aa–3ja** in both excellent yields (91–98%) and diastereoselectivities (up to >20:1) with excellent enantiose-lectivities (96–98% ee), except for the MBH carbonate with Br at the C5 position forming the product **3ba** with 9:1 dr. In addition, when the protective groups (PGs ) on nitrogen were methyl and allyl, the annulation products **3ka** and **3la** were also obtained respectively with excellent results. It is worth mentioning that the MBH carbonate derived from isatin and

The [3 + 2]-annulations of MBH adduct 1a with various cyclic sulfonimine 2 under tertiary-amine C5 catalysis were also examined. The results are summarized in Scheme 2. When the





<sup>*a*</sup>The reaction was conducted with **1a** (0.11 mmol) and **2a** (0.1 mmol) in solvent (1.0 mL) at -40 °C in the presence of 10 mol % catalyst for 2 h. <sup>*b*</sup>Isolated yields of diastereoisomer mixture. <sup>*c*</sup>The dr was determined by <sup>1</sup>H NMR spectroscopy. <sup>*d*</sup>The ee value was determined by chiral HPLC. <sup>*c*</sup>In parentheses, 1 mol % catalyst loading for 24 h. <sup>*f*</sup>In parentheses, 5 mol % catalyst loading for 5 h.

substituents were electron-donating groups on the phenyl ring, the annulation products (3aa-3ac) were obtained in high yield (96–98%) with both excellent diastereoselectivities (up to >20:1) and enantioselectivities (97–98% ee). However, when cyclic sulfonimines bearing the electron-withdrawing substituents on the phenyl ring were employed, the yields of annulation products 3ad-3af slightly decreased to 86-91% without any loss of stereoselectivities. For naphtho-cyclized sulfonimine, product 3ag was gained with excellent results either. When the ester group of the cyclic imine was replaced by a phenyl group, no cycloaddition product was obtained. Meanwhile, when the catalyst loading was decreased to 5 or 1 mol %, the corresponding products could also be obtained with similar results.

To evaluate the practicality of this [3 + 2]-cycloaddition, a gram-scale reaction of **1a** and **2b** was carried out. As shown in Scheme 3, product **3ab** was obtained in 92% yield with >20:1 dr and 97% ee under a 10 mol % catalyst loading.





On the basis of the above experimental data and literature reports,<sup>8</sup> a plausible reaction mechanism was proposed in Figure 3. The reaction was initiated through the attack of a



Figure 3. Proposed catalytic cycle and transition state.

cinchona alkaloid ( $NR_3$ ) to the MBH carbonate 1a to afford the allylic nitrogen-ylide A. Then cyclic sulfonimine 2a reacted with ylide A to generate intermediate B. Subsequent intramolecular aza-Michael addition provided the intermediate C, which could eliminate the catalyst to furnish the annulation product 3a and completed the catalytic cycle. The configuration of two newly created chiral centers in product 3ja was determined by X-ray analysis (Figure 4).<sup>12</sup> A plausible transition state for stereochemistry control was proposed in Figure 3.



In summary, we have demonstrated an organocatalytic and enantioselective [3 + 2]-annulation between isatin-derived Morita—Baylis—Hillman adducts and cyclic sulfonimines. The reaction efficiently and powerfully constructed the highly functionalized oxindole-fused spirotetrahydropyrrole frameworks in high yields with excellent enantio- and diastereoselectivities.

## ASSOCIATED CONTENT

## **Supporting Information**

Experimental procedures, characterization data, and <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HPLC spectra for new products. This material is available free of charge via the Internet at http://pubs.acs.org.

## AUTHOR INFORMATION Corresponding Author

\*E-mail: lliu@iccas.ac.cn.

#### Notes

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank the National Natural Science Foundation of China (Nos. 21372224 and 21232008), Ministry of Science and Technology (2011CB808600), and the Chinese Academy of Sciences for financial support.

#### REFERENCES

 (1) (a) Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. J. Am. Chem. Soc. 2005, 127, 10130.
 (b) Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3933. (c) Zhou, F.; Liu, Y.-L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381.

(2) (a) Baker, D. C.; Jiang, B. U.S. Patent 6,353,112 B1, 2002.
(b) Mao, J.; Baker, D. C. U.S. Patent 6,458,962 B1, 2003. (c) Yoakim, C.; O'Meara, J.; Simoneau, B.; Ogilvie, W. W.; Deziel, R. Patent Appl. WO 2004026875 A1, 2004. (d) Jirgensons, A.; Leitis, G.; Kalvinsh, I.; Robinson, D.; Finn, P.; Khan, N. Patent Appl. WO 2008142376 A1, 2008.

(3) (a) Oppolzer, W.; Wills, M.; Kelly, M. J.; Signer, M.; Blagg, J. *Tetrahedron Lett.* 1990, 31, 5015. (b) Oppolzer, W.; Wills, M.; Starkemann, C.; Bernardinelli, G. *Tetrahedron Lett.* 1990, 31, 4117.
(c) Reiser, O. Oppolzer Sultams. In *Organic Synthesis Highlights IV*; Schmalz, H.-G., Ed.; Wiley-VCH: Weinheim, 2008; pp 11–16.

(4) (a) Li, H.; Wang, Y.; Tang, L.; Deng, L. J. Am. Chem. Soc. 2004, 126, 9906. (b) Tian, S.-K; Chen, Y.; Hang, J.; Tang, L.; McDaid, P.; Deng, L. Acc. Chem. Res. 2004, 37, 621. (c) Cinchona alkaloids in synthesis and catalysis: ligands, immobilization and organocatalysis; Song, C. E., Ed.; Wiley-VCH: Weinheim, 2009.

(5) (a) Basavaiah, D.; Reddy, B. S.; Badsara, S. S. Chem. Rev. 2010, 110, 5447. (b) Masson, G.; Housseman, C.; Zhu, J. Angew. Chem., Int. Ed. 2007, 46, 4614. (c) Liu, T.-Y.; Xie, M.; Chen, Y.-C. Chem. Soc. Rev. 2012, 41, 4101. (d) Wei, Y.; Shi, M. Chem. Rev. 2013, 113, 6659.

(6) (a) Wei, Y.; Shi, M. Chem.—Asian J. 2014, 9, 2720. (b) Jiang, K.; Chen, Y.-C. Tetrahedron Lett. 2014, 55, 2049.

(7) Du, Y.; Lu, X.; Zhang, C. Angew. Chem., Int. Ed. 2003, 42, 1035.
(8) For some selected examples, see: (a) Ye, L.-W.; Sun, X.-L.; Wang, Q.-G.; Tang, Y. Angew. Chem., Int. Ed. 2007, 46, 5951. (b) Wang, Q.-G.; Zhu, S.-F.; Ye, L.-W.; Zhou, C.-Y.; Sun, X.-L.; Tang, Y.; Zhou, Q.-L. Adv. Synth. Catal. 2010, 352, 1914. (c) Deng, H.-P.; Wei, Y.; Shi, M. Org. Lett. 2011, 13, 3348. (d) Tan, B.; Candeias, N. R.; Barbas, C. F. J. Am. Chem. Soc. 2011, 4672. (e) Zhong, F.; Han, X.; Wang, Y.; Lu, Y. Angew. Chem., Int. Ed. 2011, 50, 7837. (f) Zheng, S. Q.; Lu, X. Y. Tetrahedron Lett. 2009, 50, 4532. (g) Zheng, S.; Lu, X. Org. Lett. 2009, 11, 3978. (h) Zhang, X.-N.; Deng, H.-P.; Huang, L.; Wei, Y.; Shi, M. Chem. Commun. 2012, 48, 8664. (i) Du, Y.; Feng, J.; Lu, X. Org. Lett. 2005, 7, 1987.

(9) (a) Zhong, N.-J.; Wei, F.; Xuan, Q.-Q.; Liu, L.; Wang, D.; Chen, Y.-J. *Chem. Commun.* **2013**, *49*, 11071. (b) Liu, Y.-L.; Wang, X.; Zhao, Y.-L.; Zhu, F.; Zeng, X.-P.; Chen, L.; Wang, C.-H.; Zhao, X.-L.; Zhou, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 13735. (c) Peng, J.; Huang, X.; Jiang, L.; Cui, H.-L.; Chen, Y.-C. Org. Lett. **2011**, *13*, 4584. (d) Yang, H.-B.; Zhao, Y.-Z.; Sang, R.; Wei, Y.; Shi, M. Adv. Synth. Catal. **2014**, *356*, 3799–3808.

(10) (a) Wang, T.; Shen, L.-T.; Ye, S. Synthesis 2011, 2011, 3359.
(b) Zhou, R.; Wang, C.; Song, H.; He, Z. Org. Lett. 2010, 12, 976.

(11) (a) Zhang, L.; Yu, H.; Yang, Z.; Liu, H.; Li, Z.; Guo, J.; Xiao, Y.; Guo, H. Org. Biomol. Chem. **2013**, *11*, 8235. (b) Yang, L.-J.; Cai, H.; Nie, J.; Ma, J.-A. Eur. J. Org. Chem. **2013**, 4434. (c) Tian, J.; Zhou, R.; Sun, H.; Song, H.; He, Z. J. Org. Chem. **2011**, 2374. (d) Viswambharan, B.; Selvakumar, K.; Madhavan, S.; Shanmugam, P. Org. Lett. **2010**, *12*, 2108. (e) Zheng, S.; Lu, X. Org. Lett. **2008**, *10*, 4481. (12) For details, see the Supporting Information. CCDC deposition number: 1030254